Nefiracetam – (77191-36-7)

Nefiracetam is a nootropic drug belonging to the racetam family, known for its potential cognitive-enhancing properties. It has been studied for its ability to facilitate neurotransmission in the hippocampus, a key area of the brain associated with memory and learning. Unlike other racetams such as piracetam and aniracetam, nefiracetam’s mechanism of action involves potentiation of neuronal nicotinic acetylcholine receptors, which is evident in its dose-dependent facilitation of neurotransmission in rat hippocampal slices. This effect is blocked by nicotinic acetylcholine receptor antagonists like alpha-bungarotoxin and mecamylamine, highlighting its unique mode of action.

Preliminary research suggests that nefiracetam may possess antidementia properties and could improve apathy and motivation in post-stroke patients. It has also shown antiamnesic effects in animal models against memory impairing substances such as ethanol and scopolamine. The drug’s cytoprotective actions are mediated through enhancement of GABAergic, cholinergic, and monoaminergic neuronal systems.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Nefiracetam
https://www.medchemexpress.com/nefiracetam.html
https://www.medkoo.com/products/12745
https://go.drugbank.com/drugs/DB13082
https://pubmed.ncbi.nlm.nih.gov/10869513/